BRÈVE

sur OmniGuide Holdings

OmniGuide Holdings and UROTECH announce a strategic partnership to enhance urological therapy

OmniGuide Holdings (OGH) and UROTECH®, a Medi-Globe Group entity and subsidiary of DCC plc, have recently revealed their new collaboration aimed at enriching UROTECH's technological portfolio for urologists. This partnership aims to establish a global network around RevoLix™ HTL (Hybrid Thulium Laser Therapy), targeting the treatment of kidney stones and benign prostatic hyperplasia (BPH).

As a major manufacturer in the field of minimally invasive urology, UROTECH places kidney stone treatment at the core of its mission, committing to superior product quality and clinical experience. OmniGuide, known for its advanced solutions in urological surgical therapies, will bring its expertise in robotics, precision light therapies, and biosensitivity software.

The goal of this international collaboration is to support future surgical trends by providing valuable data for urological decisions. Both companies aim to accelerate these efforts to achieve their common goal and enhance overall surgical expertise. Among the supported projects, expanding global capacity for kidney stone and BPH treatments through RevoLix™ HTL will be prioritized, as well as the development of a biosensitivity software platform.

R. E.

Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de OmniGuide Holdings